Paper - WANFANG MED ONLINE

You Position: Home > Paper

c-Jun N-terminal kinase signaling pathway in skin diseases

( views:202, downloads:26 )

Author:: No author available

Journal Title:: International Journal of Dermatology and Venereology

Issue:: 2

DOI:: 10.3760/cma.j.issn.1673-4173.2016.02.015

Key Word:: 皮肤疾病;MAP激酶信号系统;信号传导;黑色素瘤;JNK丝裂原活化蛋白激酶类;Skin diseases;MAP kinase signaling system;Signal transduction;Melanoma;JNK mitogen-activated protein kinases

Abstract： The c-Jun N-terminal kinase (JNK) is a member of the mitogen-activated protein kinase (MAPK) family,and can regulate cell growth,development,proliferation and differentiation.Aberrant expression of JNK is closely associated with occurrence and development of human skin diseases.Studies have confirmed that JNK is overexpressed and abnormally activated in the dermis/epidermis of patients with various skin diseases,which can cause abnormalities in cell growth,development,proliferation and differentiation,as well as occurrence of inflammation and apoptosis.Selective blocking of aberrant activation of the JNK signaling pathway may improve patients' condition.At present,therapies targeting the JNK signaling pathway have become a research hotspot in various skin diseases.

Reference

[1]Kannaiyan, R.,Lam, P.,Manu, K.A.,etc.Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways[J].2011,16(10).
[2]Gao Ling-juan,Gu Ping-qing,Zhao Wei,etc.The role of globular heads of the C1q receptor in HPV 16 E2-induced human cervical squamous carcinoma cell apoptosis is associated with p38 MAPK/JNK activation[J].2013,11(1).
[3]Han MJ,Wang H,Beer LA,etc.A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling.[J].2010,10(24).
[4]Micha J. Rapoport,Amir Sharabi,Dorit Aharoni,etc.Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinas[J].2005,117(3).
[5]Kanaga, Sabapathy.Role of the JNK pathway in human diseases.[J].2012,106.
[6]Burden,A.D.,Eaton,J.N.,Reich,K.,etc.Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials[J].2012,166(1).
[7]Ding,J.,Mooers,B.H.M.,Zhang,Z.,etc.After Embedding in membranes antiapoptotic bcl-xl protein binds both bcl-2 homology region 3 and helix 1 of proapoptotic bax protein to inhibit apoptotic mitochondrial permeabilization[J].2014,289(17).
[8]Rokos H,Gibbons NC,Wood JM,etc.Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo.[J].2007,127(2).
[9]C, Tournier,C, Dong,T K, Turner,etc.MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines.[J].2001,15(11).
[10]Vuillier, Françoise,Gaud, Guillaume.Loss of the HPV-Infection Resistance EVER2 Protein Impairs NF-κB Signaling Pathways in Keratinocytes.[J].2014,9(2).
[11]Karin U Schallreuter,Souna M.A Elwary,Nicholas C.J Gibbons,etc.Activation/deactivation of acetylcholinesterase by H2O2: more evidence for oxidative stress in vitiligo[J].2004,315(2).
[12]Yu,Tang.Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus.[J].2012,2012.
[13]Ghosh,D.,Tsokos,G.C.,Kyttaris,V.C..C-Jun and Ets2 proteins regulate expression of spleen tyrosine kinase in T cells[J].2012,287(15).
[14]Molad Y,Amit Vasina M,Bloch.Increased ERK and JNK activities correlate with disease activity in patients with systemic lupus erythematosus.[J].2010,69(1).
[15]Alexaki, V.-I.,Javelaud, D.,Mauviel, A..JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis[J].2008,21(4).
[16]Ryu HS,Youn SW,Yun HY,etc.Glutathione prevented dopamine-induced apoptosis of melanocytes and its signaling.[J].2007,47(2).
[17]Tournier,C.,Davies,C..Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies[J].2012,40(1).
[18]Gowda,P.S.,Zhou,F.,Chadwell,L.V.,etc.p53 binding prevents phosphatase-mediated inactivation of diphosphorylated c-Jun N-terminal kinase[J].2012,287(21).
[19]Lewis,B.J.,Rajpara,S.,Haggart,A.M.,etc.Predominance of activated, clonally expanded T helper type 17 cells within the CD4+ T cell population in psoriatic lesions[J].2013,173(1).
[20]Choi Bu Young,Choi Hong Seok,Ko Kwangseok,etc.The tumor suppressor p16INK4a prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity[J].2005,12(8).
[21]Villanova,F.,Nestle,F.O.,DiMeglio,P..Biomarkers in psoriasis and psoriatic arthritis[J].2013,72(Suppl.2).
[22]Ruth, Halaban,Wengeng, Zhang,Antonella, Bacchiocchi,etc.PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.[J].2010,23(2).
[23]Song,S.,Qiu,M.,Chu,Y.,etc.Downregulation of cellular c-Jun N-terminal protein kinase and NF-κB activation by berberine may result in inhibition of herpes simplex virus replication[J].2014,58(9).
[24]Kyriakis,J.M.,Avruch,J..Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update[J].2012,92(2).
[25]Zeng Q,Gao YJ,Cheng JK.Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model.[J].2009,219(1).
[26]Takahashi H,sahikawa-med.ac.jp,Honma M,etc.Expression of human cystatin A by keratinocytes is positively regulated via the Ras/MEKK1/MKK7/JNK signal transduction pathway but negatively regulated via the Ras/Raf-1/MEK1/ERK pathway.[J].2001,276(39).
[27]Sophie, Vriz,Silke, Reiter,Brigitte, Galliot.Cell death: a program to regenerate.[J].2014,108.